This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Apricus Biosciences, Inc. engages in developing and commercializing products and product candidates in the areas of urology and rheumatology in the United States, Canada, Europe, and internationally.View APRI key stats
Apricus Biosciences Inc - APRI - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Apricus Biosciences Inc as a
Sell with a ratings score of D.
Report Snippet: We rate APRICUS BIOSCIENCES INC (APRI) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.